IFNG and COVID-19: Importantly, we previously reported that therapy with CYT107 in a critically ill patient with COVID-19 with lymphopenia and poor T cell response to SARS-CoV-2 antigens resulted in an approximate 3-fold increase in the number of IFN-γ–producing lymphocytes that were reactive to the SARS-CoV-2 nucleocapsid and/or spike protein antigens (52).